tirzepatide phase 3 mash Eli Lilly's Zepbound improved liver scarring in mid-stage study tirzepatide in mash tirzepatide mash – Tirzepatide in Metabolically Dysfunctional‐Associated Steatohepatitis

In addition to SGLT2 inhibitors and GLP-1 receptor agonists, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated significant cardiovascular and kidney-protective effects in people with type 2 diabetes mellitus and CKD or HF [129-132]

Patients currently using compounded tirzepatide should discuss continued access with their prescriber

It is, in most respects, invisible

The association between severity of vitamin D deficiency and Hashimotos thyroiditis

The goal is not to stop weight loss

The three receptor targets explained GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves insulin secretion